MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.10
+0.21
+0.62%
After Hours: 33.90 -0.2 -0.59% 17:39 06/11 EDT
OPEN
34.25
PREV CLOSE
33.89
HIGH
34.37
LOW
33.30
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
68.39
52 WEEK LOW
24.24
MARKET CAP
2.30B
P/E (TTM)
-3.6366
1D
5D
1M
3M
1Y
5Y
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi
Zacks.com · 2d ago
Bluebird's gene therapy for β-thalassemia shows sustained and durable efficacy across pediatric and adult patients
bluebird bio (BLUE) presents data from several studies of betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia ((TDT)). A total of 63 patients have been treated
Seekingalpha · 2d ago
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for B-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
--Across Phase 3 studies, 89% (32/36) of evaluable patients across ages and genotypes achieved TI and remain transfusion free, including 91% (20/22) of evaluable pediatric patients under the age of 18
Business Wire · 2d ago
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
Zacks.com · 4d ago
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold
Zacks.com · 5d ago
Bluebird Bio Pops As FDA Allows In-Human Gene Therapy Testing To Resume
Investor's Business Daily · 6d ago
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET.
Business Wire · 6d ago
Bluebird Shares Up After FDA Lifts Clinical Holds
marketwatch.com · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLUE. Analyze the recent business situations of bluebird bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLUE stock price target is 49.00 with a high estimate of 86.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 396
Institutional Holdings: 54.95M
% Owned: 81.47%
Shares Outstanding: 67.45M
TypeInstitutionsShares
Increased
83
9.62M
New
49
3.50M
Decreased
65
2.51M
Sold Out
78
20.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Lynch
President/Chief Executive Officer/Director
Nick Leschly
Chief Financial Officer/Chief Accounting Officer
William Baird
Chief Operating Officer/Secretary
Jason Cole
Chief Scientific Officer
Philip Gregory
Other
Thomas Klima
Independent Director
John Agwunobi
Independent Director
Wendy Dixon
Independent Director
Ramy Ibrahim
Independent Director
William Sellers
Independent Director
Denice Torres
Independent Director
Mark Vachon
No Data
  • All
  • Financials
  • Insiders
More
About BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.